Aug 3, 2022 Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
Jul 5, 2022 Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
May 16, 2022 Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update
